Instrument Inactif

Communiqués Principia Biopharma Inc.

Actions

PRNB

US74257L1089

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Patient Enrollment Concluded Early in PEGASUS Phase 3 Pemphigus Trial for Rilzabrutinib	24/11/20	GL
Sanofi : completes Principia Biopharma Inc. acquisition	29/09/20	AQ
PRINCIPIA BIOPHARMA INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	28/09/20	AQ
Principia Biopharma : Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Principia Biopharma Inc.	23/09/20	AQ
Principia Biopharma : Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease	17/09/20	AQ
Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease	17/09/20	GL
Sanofi : to commence tender offer for acquisition of Principia Biopharma Inc	31/08/20	AQ
PRINCIPIA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Principia Biopharma Inc. - PRNB	20/08/20	BU
Sanofi : to acquire Principa Biopharma for $3.68 billion	20/08/20	AQ
WeissLaw LLP Investigates Principia Biopharma Inc.	18/08/20	PR
Principia Biopharma : , Novavax rise; Wells Fargo, Carnival fall	17/08/20	AQ
PRINCIPIA BIOPHARMA INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	17/08/20	AQ
PRINCIPIA BIOPHARMA : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	06/08/20	AQ
Principia Biopharma Reports Second Quarter 2020 Financial Results	06/08/20	GL
PRINCIPIA BIOPHARMA INC. : Other Events, Financial Statements and Exhibits (form 8-K)	26/06/20	AQ
Principia Biopharma : Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis	23/06/20	AQ
Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus	12/06/20	GL
PRINCIPIA BIOPHARMA INC. : Other Events, Financial Statements and Exhibits (form 8-K)	12/06/20	AQ
Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial	12/06/20	GL
PRINCIPIA BIOPHARMA INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	09/06/20	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Principia Biopharma Inc.

Actions

PRNB

US74257L1089

Communiqués

Filtres